PRINSTON INC
GenericsPRINSTON INC is a generic drug manufacturer focused on Cardiovascular, Neurology, Infectious Disease.
PRINSTON INC's Key Drugs
PRINSTON INC's core commercial portfolio centers on PAROXETINE, VYDUO, OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, spanning Cardiovascular and Neurology — its most strategically important drugs approved in the last 15 years.
Major Depressive Disorder
Hypertension
Hypertension
Hypertension
Hypertension
PRINSTON INC's Recent FDA Approvals
PRINSTON INC secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
PRINSTON INC's Therapeutic Areas
PRINSTON INC's approved drugs and pipeline span 5 therapeutic areas, led by Cardiovascular and Neurology, across 0 biologic and 0 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
PRINSTON INC's Top Competitors
PRINSTON INC's closest competitors by therapeutic-area and drug-target overlap include Merck, Novo Nordisk, and Baxter. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
PRINSTON INC Pipeline Snapshot
Active clinical trials for PRINSTON INC across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PAROXETINE leads revenue
- • 5 key drugs tracked
Trial Catalysts
- • Cardiovascular pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (5)
Discontinued (2)
Company Info
- First Approval
- 1979-10-29
- Latest
- 2026-05-20
- Applications
- 94